Your Product

Your Product

Back to main menu

Your Product

Services tailored to your product, ensuring the right development path, scalable processes, and consistent manufacturing outcomes.

Learn more
Your Stage

Your Stage

Back to main menu

Your Stage

At each stage, new challenges emerge. A single team and site ensure continuity and consistent execution across the product lifecycle.

Learn more
Our Services

Our Services

Back to main menu

Our Services

Integrated CDMO services designed for seamless progression from development through commercial manufacturing, under global regulatory standards.

Learn more
Resources

Resources

Back to main menu

Resources

Technical insights, practical guidance, and applied expertise to support decision‑making at every stage.

See all resources
About Us

About Us

Back to main menu

About Us

An overview of Groupe PARIMA, our mission, and our expertise in supporting the pharmaceutical industry.

Learn more
    En
    English
    Contact us

    Pre-Formulation Studies

    We design pre‑formulation studies around your target product profile to guide formulation strategy with measurable data.

    Drug Manufacturing banner

    Data-led formulation decisions

    Pre-formulation results clarify critical attributes and translate directly into a scientific development approach.

    Groupe PARIMA performs pre‑formulation studies to characterize critical API attributes such as PSD solid state, solubility, and stability. The resulting data guides excipient selection, compatibility assessment, and a clear path into formulation development.

    Talk to our experts

    Pre‑formulation at Groupe PARIMA builds the evidence base for robust, scalable non‑sterile formulations.

    OUR INTEGRATED ADVANTAGE

    Pre‑formulation data becomes actionable faster when carried by the same teams into formulation and scale‑up.

    Card 01

    One team, one plan

    Scientists align pre‑formulation outputs with formulation targets from day one.

    Card 02

    Actionable API data

    Results translate into excipient screening, compatibility work, and clear formulation direction.

    Card 03

    Analytical continuity

    Analytical methods are developed to detect and quantify APIs and finished products, supporting development, release, and stability testing.

    API‑Focused Pre‑Formulation Strategy

    Pre‑formulation at Groupe PARIMA focuses on the API attributes that drive formulation success. We combine solubility and stability evaluation, compatibility work, dosage‑form strategy, and QbD and DoE to improve process development that supports clinical progression

    01
    Card 01

    Solubility & Stability Evaluation

    Early screening of API solubility and stability across relevant media and stress conditions guides formulation and excipient choices.

    02
    Card 02

    Stability & Excipient Compatibility

    We assess degradation pathways, API–excipient compatibility, and product with material contact interactions to support CQA requirements.

    03
    Card 03

    Integrated Dosage Form Strategy

    We translate API attributes and the target product profile into a robust dosage‑form strategy.

    04
    Card 04

    Quality by Design and Design of Experiments

    We apply QbD and DoE to define CQAs and CPPs, establish a control strategy, and optimize robustness.

    Resources

    Access resources that explain how pre‑formulation data drives excipient selection, dosage‑form strategy, and development readiness.

    Groupe PARIMA
    2026/04/27
    How Drug Product Formulation Works: Topical, Oral, and Nasal Liquid and Semi-Solid Dosage Forms
    Read more
    Groupe PARIMA
    2026/03/18
    How Early API Characterization Can Reduce Formulation and Scale-up Risks
    Read more
    Groupe PARIMA
    2025/10/23
    Topical 101: A Guide to Complex Dermatology Formulation Development
    Read more
    Groupe PARIMA
    2026/04/27
    How Drug Product Formulation Works: Topical, Oral, and Nasal Liquid and Semi-Solid Dosage Forms
    Read more
    Groupe PARIMA
    2026/03/18
    How Early API Characterization Can Reduce Formulation and Scale-up Risks
    Read more
    Groupe PARIMA
    2025/10/23
    Topical 101: A Guide to Complex Dermatology Formulation Development
    Read more

    See all Resources

    Contact us

    Build your formulation strategy on solid data

    Start with targeted pre‑formulation work that supports QbD decisions and development-ready documentation.